Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy

• Sign Informed Consent.
• 21 years of age or older.
• Able to follow instructions and willing to attend required study visits.
• Clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion glaucoma in at least one eye (qualifying eye).
• Intra-ocular pressure (IOP) considered to be safe in both eyes in such a way that should assure clinical stability of vision and the optic nerve throughout the trial.
• Must have best corrected visual acuity of 6/60 (6/60 Snellen, 1.0 LogMAR) or better in each eye.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Presence of other primary or secondary glaucomas not listed in inclusion criterion.
• Presence of corneal dystrophies.
• Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
• Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1.
• Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment.
• Women of childbearing potential not using reliable means of birth control.
• Women who are pregnant or lactating.
• Participation in any other investigational study within 30 days prior to Visit 1.
• Current or anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial.
• Severe allergic rhinitis
• History of ocular herpes simplex.
• Other protocol-defined exclusion criteria may apply.